Table 1.
Patients’ characteristics
| Screening set (n = 63) | Validation set (n = 86) | |
|---|---|---|
|
Characteristics |
n (%) |
n (%) |
|
Histology |
|
|
| Serous |
28 (44.4) |
86 (100.0) |
| Non-serous |
35 (55.6) 1 |
- |
|
FIGO |
|
|
| I |
19 (30.2) |
6 (7.0) |
| II |
6 (9.5) |
4 (4.7) |
| III |
32 (50.8) |
61 (70.9) |
| IV |
6 (9.5) |
15 (17.4) |
|
Grade |
|
|
| Grade 1 |
10 (15.9) |
6 (7.0) |
| Grade 2 |
20 (31.7) |
19 (22.1) |
| Grade 3 |
33 (52.4) |
61 (70.9) |
|
Residual tumor |
|
|
| no |
35 (55.6) |
37 (43.0) |
| > 0 cm |
28 (44.4) |
49 (57.0) |
|
ERα |
|
|
| positive |
13 (20.6) |
27 (31.4) |
| negative |
49 (77.8) |
55 (63.9) |
| missing |
1 (1.5) |
4 (4.7) |
|
ERbeta |
|
|
| positive |
45 (71.4) |
14 (16.3) |
| negative |
15 (23.8) |
68 (79.0) |
| missing |
3 (4.7) |
4 (4.7) |
|
PELP1 |
|
|
| positive |
48 (76.2) |
21 (24.4) |
| negative |
12 (19.0) |
61 (70.9) |
| missing | 3 (4.7) | 4 (4.7) |
1Endometrioid: n= 16; Mucinous: n= 9; Undifferentiated carcinoma: n= 7; Clear cell carcinoma: n= 3;